Miss Claire Glen

  • Honorary Clinical Senior Lecturer (School of Cardiovascular & Metabolic Health)

email: Claire.Glen@glasgow.ac.uk

Room 208, BHF Glasgow Cardiovascular Research Centre, 126 University Place, G12 8TA

Import to contacts

Research interests

Research groups

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022
Number of items: 5.

2024

Glen, C. et al. (2024) Cardiovascular sequalae of trastuzumab and anthracycline in long-term survivors of breast cancer. Heart, 110(9), pp. 650-656. (doi: 10.1136/heartjnl-2023-323437) (PMID:38103912) (PMCID:PMC11041571)

2023

Glen, C., Adam, S., Coats, C. J. and Lang, N. N. (2023) Reply: Cardiotoxicity of BRAF/MEK inhibitors according to HFA/ICOS cardiotoxicity risk category. JACC: CardioOncology, 5(6), p. 850. (doi: 10.1016/j.jaccao.2023.10.003) (PMID:38204997) (PMCID:PMC10774785)

Glen, C., Adam, S., McDowell, K., Waterston, A., Tan, Y. Y., Petrie, M. C. , Coats, C. J. and Lang, N. N. (2023) Cardiotoxicity of BRAF/MEK inhibitors: a longitudinal study incorporating contemporary definitions and risk scores. JACC: CardioOncology, 5(5), pp. 628-637. (doi: 10.1016/j.jaccao.2023.04.004) (PMID:37969652) (PMCID:PMC10635885)

2022

de Wit, S., Glen, C., de Boer, R. A. and Lang, N. N. (2022) Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies. Cardiovascular Research, 118(8), pp. 3451-3466. (doi: 10.1093/cvr/cvac132) (PMID:36004495) (PMCID:PMC9897696)

Glen, C., Tan, Y. Y., Waterston, A., Evans, T. R. J. , Jones, R. J. , Petrie, M. C. and Lang, N. N. (2022) Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC: CardioOncology state-of-the-art review. JACC: CardioOncology, 4(1), pp. 1-18. (doi: 10.1016/j.jaccao.2022.01.096) (PMID:35492830) (PMCID:PMC9040125)

This list was generated on Wed Dec 25 02:13:27 2024 GMT.
Jump to: Articles
Number of items: 5.

Articles

Glen, C. et al. (2024) Cardiovascular sequalae of trastuzumab and anthracycline in long-term survivors of breast cancer. Heart, 110(9), pp. 650-656. (doi: 10.1136/heartjnl-2023-323437) (PMID:38103912) (PMCID:PMC11041571)

Glen, C., Adam, S., Coats, C. J. and Lang, N. N. (2023) Reply: Cardiotoxicity of BRAF/MEK inhibitors according to HFA/ICOS cardiotoxicity risk category. JACC: CardioOncology, 5(6), p. 850. (doi: 10.1016/j.jaccao.2023.10.003) (PMID:38204997) (PMCID:PMC10774785)

Glen, C., Adam, S., McDowell, K., Waterston, A., Tan, Y. Y., Petrie, M. C. , Coats, C. J. and Lang, N. N. (2023) Cardiotoxicity of BRAF/MEK inhibitors: a longitudinal study incorporating contemporary definitions and risk scores. JACC: CardioOncology, 5(5), pp. 628-637. (doi: 10.1016/j.jaccao.2023.04.004) (PMID:37969652) (PMCID:PMC10635885)

de Wit, S., Glen, C., de Boer, R. A. and Lang, N. N. (2022) Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies. Cardiovascular Research, 118(8), pp. 3451-3466. (doi: 10.1093/cvr/cvac132) (PMID:36004495) (PMCID:PMC9897696)

Glen, C., Tan, Y. Y., Waterston, A., Evans, T. R. J. , Jones, R. J. , Petrie, M. C. and Lang, N. N. (2022) Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC: CardioOncology state-of-the-art review. JACC: CardioOncology, 4(1), pp. 1-18. (doi: 10.1016/j.jaccao.2022.01.096) (PMID:35492830) (PMCID:PMC9040125)

This list was generated on Wed Dec 25 02:13:27 2024 GMT.